CD274 and neoplasm: Mechanistic studies revealed that K-48-modified ISGylation was formed between ISG15 and PD-L1, thus increasing ubiquitination and protein degradation of PD-L1, activating anti-tumor immune function and sensitizing ICB efficacy [140].